2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-150067
    CB1R antagonist 1 334668-69-8 99.89%
    CB1R Allosteric modulator 5, a selective cannabinoid-1 receptor (CB1R) inverse agonist with an IC50 value of 4.2 μM and EC50 value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity.
    CB1R antagonist 1
  • HY-150177
    Mannose 6 phosphate 3672-15-9 98%
    Mannose 6 phosphate is an essential precursor for mannosyl glycoconjugates, including lipid-linked oligosaccharides (LLO; glucose3mannose9GlcNAc2-P-P-dolichol) used for protein N-glycosylation. Mannose 6 phosphate causes specific LLO cleavage. Mannose 6 phosphate causes specific degradation of G3M9Gn2-P-P-Dol. Complexes containing Mannose 6 phosphate can remodel the dermal collagen network, improve skin biomechanical properties, and reverse visible signs of aging. Mannose 6 phosphate can be used in research related to skin aging.
    Mannose 6 phosphate
  • HY-150185
    RXFP2 agonist 1 2971704-58-0 98%
    RXFP2 agonist 1 (Compound 1715) is a potent RXFP2 agonist with an EC50 value of 0.06 µM. RXFP2 agonist 1 has the potential for the research of osteoporosis.
    RXFP2 agonist 1
  • HY-150191
    IMA-1 2315406-63-2 98%
    IMA-1 is an inhibitor that inhibits the interaction between arachidonic acid 12-lipoxygenase (ALOX12) and acetyl-CoA carboxylase 1 (ACC1). IMA-1 significantly blocks the progression of diet-induced non-alcoholic steatohepatitis (NASH) in male mice and crab-eating monkeys, and does not cause hyperlipidemia. IMA-1 can be used for the study of NASH.
    IMA-1
  • HY-150322
    SAR-7226 702638-25-3
    SAR-7226 is a SGLT1 and SGLT2 dual inhibitor. SAR-7226 can be used for research of type 2 diabetes.
    SAR-7226
  • HY-15042A
    (Rac)-MK 0686 1159193-97-1
    (Rac)-MK 0686 is the racemate of MK 0686. MK 0686 is a bradykinin B1 receptor antagonist.
    (Rac)-MK 0686
  • HY-150524
    UDP-Galactose 2956-16-3 98%
    UDP-Galactose is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose can be used to study cell signal transduction and substance metabolism.
    UDP-Galactose
  • HY-150723
    PBI-6DNJ 2857098-72-5 98%
    PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research.
    PBI-6DNJ
  • HY-150959
    α-Glucosidase-IN-12 2816072-24-7 98%
    α-Glucosidase-IN-12 (compound 14) is a potent α-glucosidase inhibitor, with an IC50 of 10.20 μM.
    α-Glucosidase-IN-12
  • HY-150960
    α-Glucosidase-IN-13 2816072-18-9 98%
    α-Glucosidase-IN-13 (Compound 8) is a α-glucosidase inhibitor with an IC50 of 5.69 μM.
    α-Glucosidase-IN-13
  • HY-150961
    α-Glucosidase-IN-14 2816072-15-6 98%
    α-Glucosidase-IN-14 (compound 5) is a potent α-glucosidase inhibitor, with an IC50 of 5.22 μM.
    α-Glucosidase-IN-14
  • HY-150973
    hCAII-IN-4 2816080-18-7 98%
    hCAII-IN-4 (Compound 12j) is a potent hCA II inhibitor with an IC50 of 7.78 μM. hCAII-IN-4 also inhibits β-glucuronidase with an IC50 of 773.9 μM.
    hCAII-IN-4
  • HY-150976
    β-Glucuronidase/hCAII-IN-1 2816080-17-6 98%
    β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 440.1 μM and 4.91 μM, respectively.
    β-Glucuronidase/hCAII-IN-1
  • HY-150977
    β-Glucuronidase/hCAII-IN-2 2816080-13-2 98%
    β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 670.7 μM and 21.77 μM, respectively.
    β-Glucuronidase/hCAII-IN-2
  • HY-151135
    α-Glucosidase-IN-15 2820424-85-7 98%
    α-Glucosidase-IN-15 (Compound 14B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.34 μM. α-Glucosidase-IN-15 shows antidiabetic activity.
    α-Glucosidase-IN-15
  • HY-151138
    α-Glucosidase-IN-16 1606142-34-0 98%
    α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin (HY-13753)-induced diabetic rats. Antidiabetic activity.
    α-Glucosidase-IN-16
  • HY-151141
    α-Glucosidase-IN-17 2820424-84-6 98%
    α-Glucosidase-IN-17 (Compound 12B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.79 μM. α-Glucosidase-IN-17 shows antidiabetic activity.
    α-Glucosidase-IN-17
  • HY-151142
    α-Glucosidase-IN-18 2820424-81-3 98%
    α-Glucosidase-IN-18 (7B) is an orally active α-glucosidase inhibitor with an IC50 value of 3.96 μM. α-Glucosidase-IN-18 has antidiabetic activity.
    α-Glucosidase-IN-18
  • HY-151143
    α-Glucosidase-IN-19 98%
    α-Glucosidase-IN-19 (Compound 6B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.63 μM. α-Glucosidase-IN-19 shows anti-diabetic activity.
    α-Glucosidase-IN-19
  • HY-151144
    α-Glucosidase-IN-20 420809-56-9 98%
    α-Glucosidase-IN-20 (Compound 3B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.01 μM. α-Glucosidase-IN-20 shows anti-diabetic activity.
    α-Glucosidase-IN-20
Cat. No. Product Name / Synonyms Application Reactivity